Department of Neurosciences, Ospedale Alessandro Manzoni-ASST, Lecco, Italy.
Department of Anesthesia and Intensive Care, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
J Vasc Access. 2024 Jan;25(1):100-106. doi: 10.1177/11297298221097267. Epub 2022 May 23.
Over the past decades, significant efforts have been made to reduce early and late catheter-related complications in critically ill patients, using approaches based on bundles of evidence-based interventions.
In this prospective clinical study, the authors evaluated the incidence of catheter-related complications in their neuro-intensive care unit during a 4-year period, adopting systematically the GAVeCeLT bundles for the insertion and management of all central venous access devices: centrally inserted central catheters (CICCs), peripherally inserted central catheters (PICCs) and femorally inserted central catheters (FICCs). All early/immediate and late complications were recorded.
On 486 central lines (328 CICCs, 149 PICCs and 9 FICCs), the only clinically relevant early/immediate complication was primary tip malposition (1%). In regards late infective complications, the authors did not record any case of catheter-related bloodstream infection; though, they observed one case of central line associated blood stream infection (one CICC; 0.14/1000 catheter days), and 15 cases of catheter colonization (12 CICCs and 3 PICCs; 2.09 episodes/1000 catheter days). Late non-infective complications were few: 14 accidental dislodgments (2.9%), 18 irreversible lumen occlusions (3.7%), and no episodes of symptomatic catheter-related thrombosis or tip migration.
The systematic adoption of the GAVeCeLT bundles for CVAD insertion and maintenance was associated with a minimization of catheter-related complications. The strict adherence to the recommendations included in these bundles was the major determinant for clinical success.
在过去的几十年中,人们做出了巨大的努力,通过基于循证干预措施的方案来减少重症患者的早期和晚期导管相关并发症。
在这项前瞻性临床研究中,作者在 4 年期间评估了他们神经重症监护病房中导管相关并发症的发生率,系统地采用 GAVeCeLT 方案来插入和管理所有中心静脉通路装置:中心静脉导管(CICC)、外周静脉插入的中心静脉导管(PICC)和股静脉插入的中心静脉导管(FICC)。记录所有早期/即刻和晚期并发症。
在 486 条中心静脉导管(328 条 CICC、149 条 PICC 和 9 条 FICC)中,唯一具有临床意义的早期/即刻并发症是尖端位置不当(1%)。关于晚期感染性并发症,作者未记录任何导管相关血流感染的病例;然而,他们观察到 1 例中心导管相关血流感染(1 例 CICC;0.14/1000 导管日)和 15 例导管定植(12 例 CICC 和 3 例 PICC;2.09 例/1000 导管日)。晚期非感染性并发症较少:14 例意外脱落(2.9%)、18 例不可逆转的管腔闭塞(3.7%),没有症状性导管相关性血栓形成或尖端迁移的病例。
系统采用 GAVeCeLT 方案进行 CVAD 插入和维护与导管相关并发症的最小化相关。严格遵守这些方案中包含的建议是临床成功的主要决定因素。